IQVIA (NYSE:IQV) Stock Sold Off by Rep. Kevin Hern

Key Points

• Rep. Kevin Hern sold IQVIA shares valued between $1,001 and $15,000 on September 8 from the GABRIELLE ASHTYN HERN TRUST account. He also reported additional sales of IQVIA and several other companies in mid-September.
• IQVIA was trading at $271.01, near its 52-week high of $277.40, after reporting quarterly earnings of $3.15 per share and revenue of $4.37 billion—both above analyst expectations. Revenue increased 8.7% year over year.
• Analysts maintain a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of $253.25, while institutional investors own 89.62% of the company.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of IQVIA Holdings Inc. NYSE: IQV. In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in IQVIA stock on September 8th. The trade occurred in the Representative's "GABRIELLE ASHTYN HERN TRUST" account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of CenterPoint Energy NYSE: CNP on 9/15/2026.
• Sold $1,001 - $15,000 in shares of TJX Companies NYSE: TJX on 9/15/2026.
• Sold $15,001 - $50,000 in shares of STERIS NYSE: STE on 9/15/2026.
• Sold $1,001 - $15,000 in shares of Seagate Technology NASDAQ: STX on 9/15/2026.
• Sold $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Marsh & McLennan Companies NYSE: MRSH on 9/14/2026.
• Sold $15,001 - $50,000 in shares of IQVIA NYSE: IQV on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Home Depot NYSE: HD on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Emerson Electric NYSE: EMR on 9/14/2026.

IQVIA Trading Up 0.2%

NYSE IQV opened at $271.01 on Tuesday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $277.40. The firm's fifty day simple moving average is $250.32 and its 200-day simple moving average is $203.63. The company has a market capitalization of $44.61 billion, a PE ratio of 33.62, a price-to-earnings-growth ratio of 2.31 and a beta of 1.18.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter in the previous year, the company posted $2.81 earnings per share. The business's quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.56 earnings per share for the current fiscal year.

Institutional Trading of IQVIA

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IQV. BlackRock Inc. acquired a new stake in IQVIA during the second quarter valued at approximately $2,811,292,000. Geode Capital Management LLC lifted its position in shares of IQVIA by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company's stock worth $982,272,000 after buying an additional 24,453 shares during the period. Boston Partners lifted its position in shares of IQVIA by 14.9% during the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company's stock worth $923,276,000 after buying an additional 530,672 shares during the period. JPMorgan Chase & Co. boosted its stake in IQVIA by 16.2% in the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company's stock valued at $856,468,000 after buying an additional 528,753 shares in the last quarter. Finally, Norges Bank bought a new stake in IQVIA in the fourth quarter valued at $497,445,000. Institutional investors own 89.62% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Stifel Nicolaus increased their price target on shares of IQVIA from $220.00 to $276.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. lifted their price objective on IQVIA from $225.00 to $285.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Weiss Ratings upgraded IQVIA from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday. Morgan Stanley increased their price objective on IQVIA from $240.00 to $270.00 and gave the company an "equal weight" rating in a research report on Thursday, September 17th. Finally, Royal Bank Of Canada boosted their target price on shares of IQVIA from $221.00 to $247.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and a consensus target price of $253.25.

Insider Activity at IQVIA

In related news, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the transaction, the insider directly owned 10,890 shares of the company's stock, valued at $2,845,883.70. This trade represents a 19.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the company's stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 15,581 shares of company stock valued at $3,796,021. Insiders own 1.70% of the company's stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma's 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma's 1st Congressional District. He declared candidacy for the 2026 election. Kevin Hern went into business as a McDonald's franchisee in 1999. He acquired 10 McDonald's franchises by 2012. He served on the McDonald's National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About IQVIA

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.